U.S. patent application number 16/664179 was filed with the patent office on 2020-06-18 for pharmacology of visual cycle modulators.
The applicant listed for this patent is Acucela Inc.. Invention is credited to Claes BAVIK, Nancy BOMAN, Ryo KUBOTA, Ian L. SCOTT.
Application Number | 20200188336 16/664179 |
Document ID | / |
Family ID | 43411786 |
Filed Date | 2020-06-18 |
![](/patent/app/20200188336/US20200188336A1-20200618-C00001.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00002.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00003.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00004.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00005.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00006.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00007.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00008.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00009.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00010.png)
![](/patent/app/20200188336/US20200188336A1-20200618-C00011.png)
View All Diagrams
United States Patent
Application |
20200188336 |
Kind Code |
A1 |
KUBOTA; Ryo ; et
al. |
June 18, 2020 |
PHARMACOLOGY OF VISUAL CYCLE MODULATORS
Abstract
Described herein are methods for the treatment of an ophthalmic
disease or disorder comprising the administration of non-retinoid
visual cycle modulators.
Inventors: |
KUBOTA; Ryo; (Seattle,
WA) ; BOMAN; Nancy; (Seattle, WA) ; BAVIK;
Claes; (Seattle, WA) ; SCOTT; Ian L.;
(Seattle, WA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Acucela Inc. |
Seattle |
WA |
US |
|
|
Family ID: |
43411786 |
Appl. No.: |
16/664179 |
Filed: |
October 25, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12830155 |
Jul 2, 2010 |
10471027 |
|
|
16664179 |
|
|
|
|
61266922 |
Dec 4, 2009 |
|
|
|
61222875 |
Jul 2, 2009 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/135 20130101;
A61P 3/10 20180101; A61P 25/16 20180101; A61K 31/137 20130101; A61P
31/18 20180101; A61P 25/00 20180101; Y10S 514/912 20130101; A61K
31/195 20130101; A61K 31/19 20130101; A61P 31/12 20180101; A61K
9/5078 20130101; A61P 27/02 20180101; A61P 35/00 20180101; A61K
31/166 20130101; A61P 25/28 20180101; A61P 9/10 20180101; A61K
9/0048 20130101 |
International
Class: |
A61K 31/166 20060101
A61K031/166; A61K 31/137 20060101 A61K031/137; A61K 31/135 20060101
A61K031/135; A61K 9/00 20060101 A61K009/00; A61K 9/50 20060101
A61K009/50; A61K 31/19 20060101 A61K031/19; A61K 31/195 20060101
A61K031/195 |
Claims
1.-52. (canceled)
53. A method of treating diabetic retinopathy comprising
administering daily a single oral dose of an amount from about 2 mg
to about 10 mg of a non-retinoid compound
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol having the
formula: ##STR00015##
54. The method of claim 53, wherein the normalized
electroretinogram response is from about 5% to about 15%, from
about 15% to about 25%, from about 25% to about 35%, or from about
35% to about 50%.
55. The method of claim 53, wherein the normalized
electroretinogram response is determined after about 12 hours to
about 16 hours, after about 16 hours to about 20 hours, after about
20 hours to about 24 hours, after about 24 hours to about 30 hours,
after about 30 hours to about 36 hours, after about 36 hours to
about 42 hours, post administration of said non-retinoid
compound.
56. The method of claim 53, wherein administration of a single dose
of the non-retinoid compound results in a greater normalized
electroretinogram response on day 1 than on day 2.
57. The method of claim 53, wherein administration of the
non-retinoid compound results in a greater therapeutic response on
day 2 than on day 1 after the administration of a single dose.
58. The method of claim 57, wherein the therapeutic response is
determined by electroretinography.
59. The method of claim 53, wherein administration of the
non-retinoid compound results in a normalized electroretinogram
response of less than about 50% for a time period of about 4 hours
to about 10 hours, about 10 hours to about 16 hours, about 16 hours
to about 24 hours, or about 24 hours to about 36 hours after the
plasma concentration of said non-retinoid compound has declined to
0.3 C.sub.max.
60. The method of claim 53, wherein non-retinoid compound is
administered in the morning, is administered upon waking from
sleep, or is administered upon waking from sleep in the
morning.
61. The method of claim 53, wherein the amount administered is
about 2 mg, about 5 mg, about 7 mg, or about 10 mg of the
non-retinoid compound.
62. The method of claim 53, wherein the cone response amplitude of
the electroretinogram remains within about 10%, within about 20%,
or within about 30% of the pre-treatment amplitude.
63. The method of claim 53, wherein the dosage of non-retinoid
compound is adjusted to provide no noticeable deficiency in night
vision.
64. The method of claim 53, wherein the method results in no
detectable effect on sensitivity in photopic conditions.
65. The method of claim 53, wherein the non-retinoid compound is an
in the form of a controlled-release solid dosage form.
66. The method of claim 53, wherein administration of the
controlled-release solid dosage form results in a plasma T.sub.max
12 hours post-administration.
67. The method of claim 53, wherein non-retinoid compound is
administered at a time other than the morning.
68. The method of claim 67, wherein non-retinoid compound is
administered during lunch or subsequent to lunch.
69. The method of claim 53, wherein the administration of the
non-retinoid compound results in a normalized electroretinogram
response of less than about 50% for a time period of about 4 hours
to about 36 hours after the plasma concentration of the compound
has declined to 0.3 C.sub.max following administration.
70. The method of claim 53, wherein the administration of the
non-retinoid compound results in no noticeable loss in photopic
vision.
71. The method of claim 53, wherein the administration of the
non-retinoid compound results in no noticeable deficiency in night
vision.
Description
CROSS REFERENCE
[0001] This application is a continuation of U.S. application Ser.
No. 12/830,155, filed on Jul. 2, 2010; which claims the benefit of
U.S. Provisional Application No. 61/266,922, filed Dec. 4, 2009,
and U.S. Provisional Application No. 61/222,875, filed Jul. 2,
2009, each of which is incorporated herein by reference in its
entirety.
BACKGROUND OF THE INVENTION
[0002] Neurodegenerative diseases, such as glaucoma, macular
degeneration, and Alzheimer's disease, affect millions of patients
throughout the world. The loss of quality of life associated with
these diseases is considerable.
SUMMARY OF THE INVENTION
[0003] In one aspect is a method of treating an ophthalmic disease
or disorder comprising administration of a non-retinoid compound
resulting in a normalized electroretinogram response from about 5%
to about 55% after about 12 hours to about 48 hours post
administration of said non-retinoid compound. In another aspect is
the method wherein the normalized electroretinogram response is
from about 5% to about 15%. In another aspect is the method wherein
the normalized electroretinogram response is from about 15% to
about 25%. In another aspect is the method wherein the normalized
electroretinogram response is from about 25% to about 35%. In
another aspect is the method wherein the normalized
electroretinogram response is from about 35% to about 55%. In
another aspect is the method wherein the normalized
electroretinogram response is determined after about 12 hours to
about 16 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 2 hours to
about 12 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 16 hours to
about 20 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 20 hours to
about 24 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 24 hours to
about 30 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 30 hours to
about 36 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 36 hours to
about 42 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 42 hours to
about 48 hours post administration of said non-retinoid
compound.
[0004] In one aspect is a method of treating an ophthalmic disease
or disorder comprising administration of a single dose of a
non-retinoid compound resulting in a greater normalized
electroretinogram response on day 1 than on day 2.
[0005] In one aspect is a method of treating an ophthalmic disease
or disorder comprising administration of a non-retinoid compound
resulting in a greater therapeutic response on day 2 than on day 1
after the administration of a single dose.
[0006] In another aspect is the method wherein the therapeutic
response is determined by electroretinography.
[0007] In one aspect is a method of treating an ophthalmic disease
or disorder comprising administration of a non-retinoid compound
resulting in a normalized electroretinogram response less than
about 50% for a time period of about 4 hours to about 36 hours
after the plasma concentration of said non-retinoid compound has
declined to 0.3 C.sub.max. In one aspect is the method wherein said
time period is about 4 hours to about 10 hours. In one aspect is
the method wherein said time period is about 10 hours to about 16
hours. In one aspect is the method wherein said time period is
about 16 hours to about 24 hours. In one aspect is the method
wherein said time period is about 24 hours to about 36 hours. In
another aspect is the method wherein the non-retinoid compound is
orally administered. In another aspect is the method wherein the
non-retinoid compound is administered in the morning. In another
aspect is the method wherein the non-retinoid compound is
administered upon waking from sleep. In another aspect is the
method wherein the non-retinoid compound is administered upon
waking from sleep in the morning.
[0008] In another aspect is the method wherein the wherein the
non-retinoid compound is selected from a compound of Formula (I) or
a tautomer, stereoisomer, geometric isomer or pharmaceutically
acceptable solvate, hydrate, salt, polymorph, N-oxide or prodrug
thereof:
##STR00001## [0009] wherein, [0010] Z is a bond,
--C(R.sup.1)(R.sup.2)--,
--C(R.sup.9)(R.sup.10)--C(R.sup.1)(R.sup.2)--,
--X--C(R.sup.31)(R.sup.32)--,
--C(R.sup.9)(R.sup.10)--C(R.sup.1)(R.sup.2)--C(R.sup.36)(R.sup.37)--
or --X--C(R.sup.31)(R.sup.32)--C(R.sup.1)(R.sup.2)--; [0011]
R.sup.1 and R.sup.2 are each independently selected from hydrogen,
halogen, C.sub.1-C.sub.5 alkyl, fluoroalkyl, --OR.sup.6 or
--NR.sup.7R.sup.8; or R.sup.1 and R.sup.2 together form an oxo;
[0012] R.sup.31 and R.sup.32 are each independently selected from
hydrogen, C.sub.1-C.sub.5 alkyl, or fluoroalkyl; [0013] R.sup.36
and R.sup.37 are each independently selected from hydrogen,
halogen, C.sub.1-C.sub.5 alkyl, fluoroalkyl, --OR.sup.6 or
--NR.sup.7R.sup.8; or R.sup.36 and R.sup.37 together form an oxo;
or optionally, R.sup.36 and R.sup.1 together form a direct bond to
provide a double bond; or optionally, R.sup.36 and R.sup.1 together
form a direct bond, and R.sup.37 and R.sup.2 together form a direct
bond to provide a triple bond; [0014] R.sup.3 and R.sup.4 are each
independently selected from hydrogen, alkyl, alkenyl, fluoroalkyl,
aryl, heteroaryl, carbocyclyl or C-attached heterocyclyl; or
R.sup.3 and R.sup.4 together with the carbon atom to which they are
attached, form a carbocyclyl or heterocyclyl; or R.sup.3 and
R.sup.4 together form an imino; [0015] R.sup.5 is C.sub.1-C.sub.15
alkyl, carbocyclyalkyl, arylalkyl, heteroaryl alkyl or
heterocyclylalkyl; [0016] R.sup.7 and R.sup.8 are each
independently selected from hydrogen, alkyl, carbocyclyl,
heterocyclyl, --C(.dbd.O)R.sup.13, SO.sub.2R.sup.13,
CO.sub.2R.sup.13 or SO.sub.2NR.sup.24R.sup.25; or R.sup.7 and
R.sup.8 together with the nitrogen atom to which they are attached,
form an N-heterocyclyl; [0017] X is --O--, --S--, --S(.dbd.O)--,
--S(.dbd.O).sub.2--, --N(R.sup.30)--, --C(.dbd.CH.sub.2)--,
--C(.dbd.N--NR.sup.35)--, or --C(.dbd.N--OR.sup.35)--; [0018]
R.sup.9 and R.sup.10 are each independently selected from hydrogen,
halogen, alkyl, fluoroalkyl, --OR.sup.19, --NR.sup.20R.sup.21 or
carbocyclyl; or R.sup.9 and R.sup.10 form an oxo; or optionally,
R.sup.9 and R.sup.1 together form a direct bond to provide a double
bond; or optionally, R.sup.9 and R.sup.1 together form a direct
bond, and R.sup.10 and R.sup.2 together form a direct bond to
provide a triple bond; [0019] R.sup.11 and R.sup.12 are each
independently selected from hydrogen, alkyl, carbocyclyl,
--C(.dbd.O)R.sup.23, --C(NH)NH.sub.2, SO.sub.2R.sup.23,
CO.sub.2R.sup.23 or SO.sub.2NR.sup.28R.sup.29; or R.sup.11 and
R.sup.12, together with the nitrogen atom to which they are
attached, form an N-heterocyclyl; [0020] each R.sup.13, R.sup.22
and R.sup.23 is independently selected from alkyl, heteroalkyl,
alkenyl, aryl, aralkyl, carbocyclyl, heteroaryl or heterocyclyl;
[0021] R.sup.6, R.sup.19, R.sup.30, R.sup.34 and R.sup.35 are each
independently hydrogen or alkyl; [0022] R.sup.20 and R.sup.21 are
each independently selected from hydrogen, alkyl, carbocyclyl,
heterocyclyl, --C(.dbd.O)R.sup.22, SO.sub.2R.sup.22,
CO.sub.2R.sup.22 or SO.sub.2NR.sup.26R.sup.27; or R.sup.20 and
R.sup.21 together with the nitrogen atom to which they are
attached, form an N-heterocyclyl; and [0023] each R.sup.24,
R.sup.25, R.sup.26, R.sup.27, R.sup.28 and R.sup.29 is
independently selected from hydrogen, alkyl, alkenyl, fluoroalkyl,
aryl, heteroaryl, carbocyclyl or heterocyclyl; [0024] each R.sup.33
is independently selected from halogen, OR.sup.34, alkyl, or
fluoroalkyl; and n is 0, 1, 2, 3, or 4.
[0025] In another aspect is the method wherein the compound of
Formula (I) has the structure of Formula (II):
##STR00002## [0026] wherein, [0027] R.sup.1 and R.sup.2 are each
independently selected from hydrogen, halogen, C.sub.1-C.sub.5
alkyl, luoroalkyl, --OR.sup.6 or --NR.sup.7R.sup.8, or R.sup.1 and
R.sup.2 together form an oxo; [0028] R.sup.3 and R.sup.4 are each
independently selected from hydrogen or alkyl; or R.sup.3 and
R.sup.4 together form an imino; [0029] R.sup.7 and R.sup.8 are each
independently selected from hydrogen, alkyl, carbocyclyl or
--C(.dbd.O)R.sup.13; or R.sup.7 and R.sup.8, together with the
nitrogen atom to which they are attached, form an N-heterocyclyl;
[0030] R.sup.9 and R.sup.10 are each independently selected from
hydrogen, halogen, alkyl, fluoroalkyl, --OR.sup.19,
--NR.sup.20R.sup.21 or carbocyclyl; or R.sup.9 and R.sup.10
together form an oxo; [0031] R.sup.11 and R.sup.12 are each
independently selected from hydrogen, alkyl, carbocyclyl or
--C(.dbd.O)R.sup.23; or R.sup.11 and R.sup.12, together with the
nitrogen atom to which they are attached, form an N-heterocyclyl;
[0032] each R.sup.13, R.sup.22 and R.sup.23 is independently
selected from alkyl, alkenyl, aryl, aralkyl, carbocyclyl,
heteroaryl or heterocyclyl; [0033] R.sup.6, R.sup.19 and R.sup.34
are each independently hydrogen or alkyl; [0034] R.sup.20 and
R.sup.21 are each independently selected from hydrogen, alkyl,
carbocyclyl, --C(.dbd.O)R.sup.22; or R.sup.20 and R.sup.21,
together with the nitrogen atom to which they are attached, form an
N-heterocyclyl; and [0035] each R.sup.24, R.sup.25, R.sup.26,
R.sup.27, R.sup.28 and R.sup.29 is independently selected from
hydrogen, alkyl, alkenyl, fluoroalkyl, aryl, heteroaryl,
carbocyclyl or heterocyclyl; [0036] R.sup.14 and R.sup.15 are each
independently selected from hydrogen or alkyl; [0037] R.sup.16 and
R.sup.17 are each independently selected from hydrogen,
C.sub.1-C.sub.13 alkyl, halo or fluoroalkyl; or R.sup.16 and
R.sup.17, together with the carbon to which they are attached form
a carbocyclyl; [0038] each R.sup.33 is independently selected from
halogen, OR.sup.34, alkyl, or fluoroalkyl; and n is 0, 1, 2, 3, or
4; and [0039] R.sup.18 is selected from a hydrogen, alkyl, alkoxy,
hydroxy, halo or fluoroalkyl.
[0040] In another aspect is the method wherein the compound of
Formula (II) is further defined as [0041] R.sup.1 and R.sup.2 are
each independently selected from hydrogen, halogen, C.sub.1-C.sub.5
alkyl, or --OR.sup.6; [0042] R.sup.9 and R.sup.10 are each
independently selected from hydrogen, halogen, alkyl, or
--OR.sup.19; or [0043] R.sup.9 and R.sup.10 together form an oxo;
[0044] R.sup.6 and R.sup.19 are each independently hydrogen or
alkyl; [0045] R.sup.16 and R.sup.17, together with the carbon to
which they are attached form a carbocyclyl; and [0046] R.sup.18 is
selected from a hydrogen, alkoxy or hydroxy.
[0047] In another aspect is the method wherein the compound of
Formula (II) is further defined as R.sup.16 and R.sup.17, together
with the carbon to which they are attached, form a cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, and R.sup.18
is hydrogen or hydroxy.
[0048] In another aspect is the method wherein the compound of
Formula (II) is
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1ol.
[0049] In another aspect is the method for treating an ophthalmic
disease or disorder comprising administration of a non-retinoid
compound wherein the non-retinoid compound, or tautomer,
stereoisomer, geometric isomer, pharmaceutically acceptable
solvate, hydrate, salt, polymorph, N-oxide or prodrug thereof, is
selected from the group consisting of:
##STR00003## ##STR00004##
[0050] In another aspect is the method wherein the dose is from
about 4 mg to about 100 mg. In another aspect is the method wherein
the dose is about 75 mg. In another aspect is the method wherein
the dose is about 60 mg. In another aspect is the method wherein
the dose is about 40 mg.
[0051] In another aspect is the method wherein the dose is about 20
mg. In another aspect is the method wherein the dose is about 7 mg.
In another aspect is the method wherein the dose is about 5 mg.
[0052] In one aspect is the method of determining the dose to be
administered for the treatment of an ophthalmic disease or disorder
by administration of a non-retinoid visual cycle modulator
comprising determining the normalized electroretinogram response
from about 12 hours to about 48 hours after the administration of a
single dose of said non-retinoid visual cycle modulator. In another
aspect is the method of determining the dose to be administered for
the treatment of an ophthalmic disease or disorder by
administration of a non-retinoid visual cycle modulator comprising
determining the normalized electroretinogram response from about 2
hours to about 12 hours after the administration of a single dose
of said non-retinoid visual cycle modulator.
[0053] In one aspect is a controlled-release solid dosage form for
the treatment of an ophthalmic disease or disorder comprising a
compound of Formula (I) wherein the plasma T.sub.max is observed 12
hours post-dose.
[0054] In one asepct is a dosing schedule for the treatment of an
ophthalmic disease or disorder comprising a drug holiday after from
about 3 months of continuous daily dosing to about 12 months of
continuous daily dosing. In another aspect is a dosing schedule
wherein the drug holiday is a time period of from about 3 days to
about 21 days. In another aspect is a dosing schedule wherein the
drug holiday is a time period of from about 1 month to about 2
months. In another aspect is the method wherein the ophthalmic
disease or disorder is selected from retinal detachment,
hemorrhagic retinopathy, retinitis pigmentosa, cone-rod dystrophy,
Sorsby's fundus dystrophy, optic neuropathy, inflammatory retinal
disease, diabetic retinopathy, diabetic maculopathy, retinal blood
vessel occlusion, retinopathy of prematurity, ischemia reperfusion
related retinal injury, proliferative vitreoretinopathy, retinal
dystrophy, hereditary optic neuropathy, Sorsby's fundus dystrophy,
uveitis, a retinal injury, a retinal disorder associated with
Alzheimer's disease, a retinal disorder associated with multiple
sclerosis, a retinal disorder associated with Parkinson's disease,
a retinal disorder associated with viral infection, a retinal
disorder related to light overexposure, myopia, and a retinal
disorder associated with AIDS. In another aspect is the method
wherein the ophthalmic disease or disorder is age-related macular
degeneration or Stargardt's macular dystrophy. In another aspect is
the method wherein the ophthalmic disease or disorder is dry
age-related macular degeneration. In another aspect is the method
wherein the ophthalmic disease or disorder is diabetic
retinopathy.
[0055] One embodiment provides the compound, or tautomer,
stereoisomer, geometric isomer, pharmaceutically acceptable
solvate, hydrate, salt, polymorph, N-oxide or prodrug thereof,
selected from:
##STR00005## ##STR00006##
Incorporation by Reference
[0056] All publications and patent applications mentioned in this
specification are herein incorporated by reference for the purposes
cited.
BRIEF DESCRIPTION OF THE DRAWINGS
[0057] The novel features of the invention are set forth with
particularity in the appended claims. A better understanding of the
features and advantages of the present invention will be obtained
by reference to the following detailed description that sets forth
illustrative embodiments, in which the principles of the invention
are utilized, and the accompanying drawings.
[0058] FIG. 1 provides an illustrative linear scale plot of plasma
concentration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol vs time
after administration of a single oral dose.
[0059] FIG. 2 provides an illustrative log scale plot of plasma
concentration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol vs time
after administration of a single oral dose.
[0060] FIG. 3 provides an illustrative single patient EGR response
vs retinal illumination time at days 1, 2 and 7, compared to
baseline (no drug treatment) after administration of a single oral
dose of (R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol.
FIG. 3(a) is for the 20 mg dose; FIG. 3(b) is for the 40 mg dose;
and FIG. 3(c) is for the 60 mg dose.
[0061] FIG. 4 provides an illustrative normalized EGR response vs
retinal illumination time at day 1 (4 hours post dosing), compared
to baseline (no drug treatment) after administration of a single
oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. The doses
examined are 20 mg, 40 mg, 60 mg and 75 mg.
[0062] FIG. 5 provides an illustrative normalized EGR response vs
retinal illumination time at day 2 (24 hours post dosing), compared
to baseline (no drug treatment) after administration of a single
oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. The doses
examined are 20 mg, 40 mg, 60 mg and 75 mg.
[0063] FIG. 6 provides an illustrative table comparing the
inhibition of normalized EGR response after 30 minutes of retinal
illumination vs single oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. Day 1
measurements were obtained at 4 hours post dose and day 2
measurements were obtained at 24 hours post dose.
[0064] FIG. 7 provides an illustrative normalized EGR response vs
retinal illumination time, compared to baseline (no drug treatment)
after administration of a single 75 mg oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol at 1 day (4
hours post dose), day 2 (24 hours post dose), day 4 and day 7.
[0065] FIG. 8 provides an illustrative table comparing the
inhibition of normalized EGR response after 30 minutes of retinal
illumination vs length of time after administration of a single 75
mg oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. Day 1
measurements were obtained at 4 hours post dose and day 2
measurements were obtained at 24 hours post dose.
[0066] FIG. 9 provides the plasma concentration versus time graph
as determined by the study described in Example 1.
[0067] FIG. 10 provides the ERG data collection sequence utilized
in the study described in Example 1.
[0068] FIG. 11 provides the Day 2 ERG response curve obtained as
described in Example 1.
[0069] FIG. 12 provides a summary of the ERG suppression data
obtained as described in Example 1.
[0070] FIG. 13 provides the cone response curve as determined by
the study described in Example 1.
DETAILED DESCRIPTION OF THE INVENTION
[0071] We recognize a need for an effective treatment for treating
ophthalmic diseases or disorders resulting in ophthalmic
dysfunction including those described above. In particular, we
recognize a need for compositions and methods for treating
Stargardt's disease and age-related macular degeneration (AMD)
without causing further unwanted side effects such as progressive
retinal degeneration, LCA-like conditions, achromatopsia, night
blindness or delayed dark adaptation, or systemic vitamin A
deficiency. We also recognize a need for effective treatments for
other ophthalmic diseases and disorders that adversely affect the
retina.
[0072] Age-related macular degeneration (AMD) affects between ten
and fifteen million patients in the United States, and it is the
leading cause of blindness in aging populations worldwide. AMD
affects central vision and causes the loss of photoreceptor cells
in the central part of retina called the macula. Macular
degeneration can be classified into two types: dry-form and
wet-form. The dry-form is more common than the wet; about 90% of
age-related macular degeneration patients are diagnosed with the
dry-form. The wet-form of the disease and geographic atrophy, which
is the end-stage phenotype of dry-form AMD, causes the most serious
vision loss. All patients who develop wet-form AMD are believed to
previously have developed dry-form AMD for a prolonged period of
time. The exact causes of AMD are still unknown. The dry-form of
AMD may result from the senescence and thinning of macular tissues
associated with the deposition of pigment in the macular retinal
pigment epithelium. In wet-form AMD, new blood vessels grow beneath
the retina, form scar tissue, bleed, and leak fluid. The overlying
retina can be severely damaged, creating "blind" areas in the
central vision.
[0073] For the vast majority of patients who have the dry-form of
AMD, no effective treatment is yet available. Because the dry-form
of AMD precedes development of the wet-form of AMD, therapeutic
intervention to prevent or delay disease progression in the
dry-form AMD would benefit patients with dry-form of AMD and might
reduce the incidence of the wet-form of AMD.
[0074] Decline of vision noticed by the patient or characteristic
features detected by an ophthalmologist during a routine eye exam
may be the first indicator of AMD. The formation of "drusen," or
membranous debris beneath the retinal pigment epithelium of the
macula is often the first physical sign that AMD is developing.
Late symptoms include the perceived distortion of straight lines
and, in advanced cases, a dark, blurry area or area with absent
vision appears in the center of vision; and/or there may be color
perception changes.
[0075] Different forms of genetically-linked macular degenerations
may also occur in younger patients. In other maculopathies, factors
in the disease are heredity, nutritional, traumatic, infection, or
other ecologic factors.
[0076] Glaucoma is a broad term used to describe a group of
diseases that causes a slowly progressive visual field loss,
usually asymptomatically. The lack of symptoms may lead to a
delayed diagnosis of glaucoma until the terminal stages of the
disease. The prevalence of glaucoma is estimated to be 2.2 million
in the United States, with about 120,000 cases of blindness
attributable to the condition. The disease is particularly
prevalent in Japan, which has four million reported cases. In many
parts of the world, treatment is less accessible than in the United
States and Japan, thus glaucoma ranks as a leading cause of
blindness worldwide. Even if subjects afflicted with glaucoma do
not become blind, their vision is often severely impaired.
[0077] The progressive loss of peripheral visual field in glaucoma
is caused by the death of ganglion cells in the retina. Ganglion
cells are a specific type of projection neuron that connects the
eye to the brain. Glaucoma is usually accompanied by an increase in
intraocular pressure. Current treatment includes use of drugs that
lower the intraocular pressure; however, contemporary methods to
lower the intraocular pressure are often insufficient to completely
stop disease progression. Ganglion cells are believed to be
susceptible to pressure and may suffer permanent degeneration prior
to the lowering of intraocular pressure. An increasing number of
cases of normal-tension glaucoma are observed in which ganglion
cells degenerate without an observed increase in the intraocular
pressure. Current glaucoma drugs only treat intraocular pressure
and are ineffective in preventing or reversing the degeneration of
ganglion cells.
[0078] Recent reports suggest that glaucoma is a neurodegenerative
disease, similar to Alzheimer's disease and Parkinson's disease in
the brain, except that it specifically affects retinal neurons. The
retinal neurons of the eye originate from diencephalon neurons of
the brain. Though retinal neurons are often mistakenly thought not
to be part of the brain, retinal cells are key components of the
central nervous system, interpreting the signals from the
light-sensing cells.
[0079] Alzheimer's disease (AD) is the most common form of dementia
among the elderly. Dementia is a brain disorder that seriously
affects a person's ability to carry out daily activities.
Alzheimer's is a disease that affects four million people in the
United States alone. It is characterized by a loss of nerve cells
in areas of the brain that are vital to memory and other mental
functions. Currently available drugs can ameliorate AD symptoms for
a relatively finite period of time, but no drugs are available that
treat the disease or completely stop the progressive decline in
mental function. Recent research suggests that glial cells that
support the neurons or nerve cells may have defects in AD
sufferers, but the cause of AD remains unknown. Individuals with AD
seem to have a higher incidence of glaucoma and age-related macular
degeneration, indicating that similar pathogenesis may underlie
these neurodegenerative diseases of the eye and brain. (See Giasson
et al., Free Radic. Biol. Med. 32:1264-75 (2002); Johnson et al.,
Proc. Natl. Acad. Sci. USA 99:11830-35 (2002); Dentchev et al.,
Mol. Vis. 9:184-90 (2003)).
[0080] Neuronal cell death underlies the pathology of these
diseases. Unfortunately, very few compositions and methods that
enhance retinal neuronal cell survival, particularly photoreceptor
cell survival, have been discovered. A need therefore exists to
identify and develop compositions that can be used for treatment
and prophylaxis of a number of retinal diseases and disorders that
have neuronal cell death as a primary, or associated, element in
their pathogenesis.
[0081] In vertebrate photoreceptor cells, the irradiance of a
photon causes isomerization of 11-cis-retinylidene chromophore to
all-trans-retinylidene and uncoupling from the visual opsin
receptors. This photoisomerization triggers conformational changes
of opsins, which, in turn, initiate the biochemical chain of
reactions termed phototransduction (Filipek et al., Annu. Rev.
Physiol. 65:851-79 (2003)). Regeneration of the visual pigments
requires that the chromophore be converted back to the
11-cis-configuration in the processes collectively called the
retinoid (visual) cycle (see, e.g., McBee et al., Prog. Retin. Eye
Res. 20:469-52 (2001)). First, the chromophore is released from the
opsin and reduced in the photoreceptor by retinol dehydrogenases.
The product, all-trans-retinol, is trapped in the adjacent retinal
pigment epithelium (RPE) in the form of insoluble fatty acid esters
in subcellular structures known as retinosomes (Imanishi et al., J.
Cell Biol. 164:373-87 (2004)).
[0082] In Stargardt's disease (Allikmets et al., Nat. Genet.
15:236-46 (1997)), a disease associated with mutations in the ABCR
transporter that acts as a flippase, the accumulation of
all-trans-retinal may be responsible for the formation of a
lipofuscin pigment, A2E, which is toxic towards retinal pigment
epithelial cells and causes progressive retinal degeneration and,
consequently, loss of vision (Mata et al., Proc. Natl. Acad. Sci.
USA 97:7154-59 (2000); Weng et al., Cell 98:13-23 (1999)). Treating
patients with an inhibitor of retinol dehydrogenases, 13-cis-RA
(Isotretinoin, Accutane.RTM., Roche), has been considered as a
therapy that might prevent or slow the formation of A2E and might
have protective properties to maintain normal vision (Radu et al.,
Proc. Natl. Acad. Sci. USA 100:4742-47 (2003)). 13-cis-RA has been
used to slow the synthesis of 11-cis-retinal by inhibiting
11-cis-RDH (Law et al., Biochem. Biophys. Res. Commun. 161:825-9
(1989)), but its use can also be associated with significant night
blindness. Others have proposed that 13-cis-RA works to prevent
chromophore regeneration by binding RPE65, a protein essential for
the isomerization process in the eye (Gollapalli et al., Proc.
Natl. Acad. Sci. USA 101:10030-35 (2004)). Gollapalli et al.
reported that 13-cis-RA blocked the formation of A2E and suggested
that this treatment may inhibit lipofuscin accumulation and, thus,
delay either the onset of visual loss in Stargardt's disease or
age-related macular degeneration, which are both associated with
retinal pigment-associated lipofuscin accumulation. However,
blocking the retinoid cycle and forming unliganded opsin may result
in more severe consequences and worsening of the patient's
prognosis (see, e.g., Van Hooser et al., J. Biol. Chem.
277:19173-82 (2002); Woodruff et al., Nat. Genet. 35:158-164
(2003)). Failure of the chromophore to form may lead to progressive
retinal degeneration and may produce a phenotype similar to Leber
Congenital Amaurosis (LCA), which is a very rare genetic condition
affecting children shortly after birth.
Definitions
[0083] As used in the specification and appended claims, unless
specified to the contrary, the following terms have the meaning
indicated:
[0084] As used herein and in the appended claims, the singular
forms "a," "and," and "the" include plural referents unless the
context clearly dictates otherwise. Thus, for example, reference to
"a compound" includes a plurality of such compounds, and reference
to "the cell" includes reference to one or more cells (or to a
plurality of cells) and equivalents thereof known to those skilled
in the art, and so forth. When ranges are used herein for physical
properties, such as molecular weight, or chemical properties, such
as chemical formulae, all combinations and subcombinations of
ranges and specific embodiments therein are intended to be
included. The term "about" when referring to a number or a
numerical range means that the number or numerical range referred
to is an approximation within experimental variability (or within
statistical experimental error), and thus the number or numerical
range may vary between 1% and 15% of the stated number or numerical
range. The term "comprising" (and related terms such as "comprise"
or "comprises" or "having" or "including") is not intended to
exclude that in other certain embodiments, for example, an
embodiment of any composition of matter, composition, method, or
process, or the like, described herein, may "consist of" or
"consist essentially of" the described features.
[0085] "Amino" refers to the --H.sub.2radical.
[0086] "Cyano" refers to the --CN radical.
[0087] "Nitro" refers to the --NO.sub.2 radical.
[0088] "Oxa" refers to the --O-- radical.
[0089] "Oxo" refers to the .dbd.O radical.
[0090] "Thioxo" refers to the .dbd.S radical.
[0091] "Imino" refers to the .dbd.N--H radical.
[0092] "Hydrazino" refers to the .dbd.N--NH.sub.2 radical.
[0093] "Alkyl" refers to a straight or branched hydrocarbon chain
radical consisting solely of carbon and hydrogen atoms, containing
no unsaturation, having from one to fifteen carbon atoms (e.g.,
C.sub.1-C.sub.15 alkyl). In certain embodiments, an alkyl comprises
one to thirteen carbon atoms (e.g., C.sub.1-C.sub.13 alkyl). In
certain embodiments, an alkyl comprises one to eight carbon atoms
(e.g., C.sub.1-C.sub.8 alkyl). In other embodiments, an alkyl
comprises five to fifteen carbon atoms (e.g., C.sub.5-C.sub.15
alkyl). In other embodiments, an alkyl comprises five to eight
carbon atoms (e.g., C.sub.5-C.sub.8 alkyl). The alkyl is attached
to the rest of the molecule by a single bond, for example, methyl
(Me), ethyl (Et), n-propyl, 1-methylethyl (iso-propyl), n-butyl,
n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl,
2-methylhexyl, and the like. Unless stated otherwise specifically
in the specification, an alkyl group is optionally substituted by
one or more of the following substituents: halo, cyano, nitro, oxo,
thioxo, trimethylsilanyl, --OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a,
--N(R.sup.a).sub.2, --C(O)OR.sup.a, --C(O )OR.sup.a,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --(R.sup.a)S(O).sub.tR.sup.a(where t is 1
or 2), --S(O).sub.tOR.sup.a (where t is 1 or 2) and
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2) where each R.sup.a
is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl,
carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl,
heteroaryl or heteroarylalkyl.
[0094] "Alkenyl" refers to a straight or branched hydrocarbon chain
radical group consisting solely of carbon and hydrogen atoms,
containing at least one double bond, and having from two to twelve
carbon atoms. In certain embodiments, an alkenyl comprises two to
eight carbon atoms. In other embodiments, an alkenyl comprises two
to four carbon atoms. The alkenyl is attached to the rest of the
molecule by a single bond, for example, ethenyl (i.e., vinyl),
prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl,
penta-1,4-dienyl, and the like. Unless stated otherwise
specifically in the specification, an alkenyl group is optionally
substituted by one or more of the following substituents: halo,
cyano, nitro, oxo, thioxo, trimethylsilanyl, --OR.sup.a,
--SR.sup.a, --OC(O)--R.sup.a, --(R.sup.a).sub.2, --C(O)R.sup.a,
--(O)OR.sup.a, --C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --(R.sup.a)S(O).sub.tR.sup.a (where t is 1
or 2), --S(O).sub.tOR.sup.a (where t is 1 or 2) and
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2) where each R.sup.a
is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl,
carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl,
heteroaryl or heteroarylalkyl.
[0095] "Alkynyl" refers to a straight or branched hydrocarbon chain
radical group consisting solely of carbon and hydrogen atoms,
containing at least one triple bond, having from two to twelve
carbon atoms. In certain embodiments, an alkynyl comprises two to
eight carbon atoms. In other embodiments, an alkynyl has two to
four carbon atoms. The alkynyl is attached to the rest of the
molecule by a single bond, for example, ethynyl, propynyl, butynyl,
pentynyl, hexynyl, and the like. Unless stated otherwise
specifically in the specification, an alkynyl group is optionally
substituted by one or more of the following substituents: halo,
cyano, nitro, oxo, thioxo, trimethylsilanyl, --OR.sup.a,
--SR.sup.a, --OC(O)--R.sup.a, --N(R.sup.a).sub.2, --(O)R.sup.a,
--C(O)OR.sup.a, --C(O)N(R.sup.a).sub.2,--N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)S(O).sub.tR.sup.a (where t is
1 or 2), --S(O).sub.tOR.sup.a (where t is 1 or 2) and
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2) where each R.sup.a
is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl,
carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl,
heteroaryl or heteroarylalkyl.
[0096] "Alkylene" or "alkylene chain" refers to a straight or
branched divalent hydrocarbon chain linking the rest of the
molecule to a radical group, consisting solely of carbon and
hydrogen, containing no unsaturation and having from one to twelve
carbon atoms, for example, methylene, ethylene, propylene,
n-butylene, and the like. The alkylene chain is attached to the
rest of the molecule through a single bond and to the radical group
through a single bond. The points of attachment of the alkylene
chain to the rest of the molecule and to the radical group can be
through one carbon in the alkylene chain or through any two carbons
within the chain. Unless stated otherwise specifically in the
specification, an alkylene chain is optionally substituted by one
or more of the following substituents: halo, cyano, nitro, aryl,
cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo,
trimethylsilanyl, --OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a,
--N(R.sup.a).sub.2, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)S(O).sub.tR.sup.a (where t is
1 or 2), --S(O).sub.tOR.sup.a (where t is 1 or 2) and
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2) where each R.sup.a
is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl,
carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl,
heteroaryl or heteroarylalkyl.
[0097] "Alkenylene" or "alkenylene chain" refers to a straight or
branched divalent hydrocarbon chain linking the rest of the
molecule to a radical group, consisting solely of carbon and
hydrogen, containing at least one double bond and having from two
to twelve carbon atoms, for example, ethenylene, propenylene,
n-butenylene, and the like. The alkenylene chain is attached to the
rest of the molecule through a double bond or a single bond and to
the radical group through a double bond or a single bond. The
points of attachment of the alkenylene chain to the rest of the
molecule and to the radical group can be through one carbon or any
two carbons within the chain. Unless stated otherwise specifically
in the specification, an alkenylene chain is optionally substituted
by one or more of the following substituents: halo, cyano, nitro,
aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo,
trimethylsilanyl, --OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a,
--N(R.sup.a).sub.2, --C(O)R.sup.a, --C(O)OR.sup.a,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)S(O).sub.tR.sup.a (where t is
1 or 2), --S(O).sub.tOR.sup.a (where t is 1 or 2) and
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2) where each R.sup.a
is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl,
cycloalkylalkyl, aryl (optionally substituted with one or more halo
groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or
heteroarylalkyl, and where each of the above substituents is
unsubstituted unless otherwise indicated.
[0098] "Aryl" refers to a radical derived from an aromatic
monocyclic or multicyclic hydrocarbon ring system by removing a
hydrogen atom from a ring carbon atom. The aromatic monocyclic or
multicyclic hydrocarbon ring system contains only hydrogen and
carbon from six to eighteen carbon atoms, where at least one of the
rings in the ring system is fully unsaturated, i.e., it contains a
cyclic, delocalized (4n+2) .pi.-electron system in accordance with
the Huckel theory. Aryl groups include, but are not limited to,
groups such as phenyl, fluorenyl, and naphthyl. Unless stated
otherwise specifically in the specification, the term "aryl" or the
prefix "ar-" (such as in "aralkyl") is meant to include aryl
radicals optionally substituted by one or more substituents
independently selected from alkyl, alkenyl, alkynyl, halo,
fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted aralkenyl, optionally
substituted aralkynyl, optionally substituted carbocyclyl,
optionally substituted carbocyclylalkyl, optionally substituted
heterocyclyl, optionally substituted heterocyclylalkyl, optionally
substituted heteroaryl, optionally substituted heteroarylalkyl,
--R.sup.b--OR.sup.a, --R.sup.b--OC(O)--R.sup.a,
--R.sup.b--N(R.sup.a).sub.2l , --R.sup.b--C(O)R.sup.a,
--R.sup.b--C(O)OR.sup.a, --R.sup.b--C(O)N(R.sup.a).sub.2,
--R.sup.b--O--R.sup.c--C(O)N(R.sup.a).sub.2,
--R.sup.b--N(R.sup.a)C(O)OR.sup.a,
--R.sup.b--N(R.sup.a)C(O)R.sup.a,
--R.sup.b--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--R.sup.b--S(O).sub.tOR.sup.a (where t is 1 or 2) and
--R.sup.b--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), where
each R.sup.a is independently hydrogen, alkyl, fluoroalkyl,
cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one
or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl,
heteroaryl or heteroarylalkyl, each R.sup.b is independently a
direct bond or a straight or branched alkylene or alkenylene chain,
and R.sup.c is a straight or branched alkylene or alkenylene chain,
and where each of the above sub stituents is unsubstituted unless
otherwise indicated.
[0099] "Aralkyl" refers to a radical of the formula --R.sup.c-aryl
where R.sup.c is an alkylene chain as defined above, for example,
benzyl, diphenylmethyl and the like. The alkylene chain part of the
aralkyl radical is optionally substituted as described above for an
alkylene chain. The aryl part of the aralkyl radical is optionally
substituted as described above for an aryl group.
[0100] "Aralkenyl" refers to a radical of the formula
--R.sup.d-aryl where R.sup.d is an alkenylene chain as defined
above. The aryl part of the aralkenyl radical is optionally
substituted as described above for an aryl group. The alkenylene
chain part of the aralkenyl radical is optionally substituted as
defined above for an alkenylene group.
[0101] "Aralkynyl" refers to a radical of the formula
--R.sup.c-aryl, where R.sup.c is an alkynylene chain as defined
above. The aryl part of the aralkynyl radical is optionally
substituted as described above for an aryl group. The alkynylene
chain part of the aralkynyl radical is optionally substituted as
defined above for an alkynylene chain.
[0102] "Carbocyclyl" refers to a stable non-aromatic monocyclic or
polycyclic hydrocarbon radical consisting solely of carbon and
hydrogen atoms, which may include fused or bridged ring systems,
having from three to fifteen carbon atoms. In certain embodiments,
a carbocyclyl comprises three to ten carbon atoms. In other
embodiments, a carbocyclyl comprises five to seven carbon atoms.
The carbocyclyl is attached to the rest of the molecule by a single
bond. Carbocyclyl may be saturated, (i.e., containing single C--C
bonds only) or unsaturated (i.e., containing one or more double
bonds or triple bonds.) A fully saturated carbocyclyl radical is
also referred to as "cycloalkyl." Examples of monocyclic
cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, and cyclooctyl. An unsaturated carbocyclyl
is also referred to as "cycloalkenyl." Examples of monocyclic
cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl,
cycloheptenyl, and cyclooctenyl. Polycyclic carbocyclyl radicals
include, for example, adamantyl, norbornyl (i.e.,
bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl,
7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise
stated specifically in the specification, the term "carbocyclyl" is
meant to include carbocyclyl radicals that are optionally
substituted by one or more substituents independently selected from
alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano,
nitro, optionally substituted aryl, optionally substituted aralkyl,
optionally substituted aralkenyl, optionally substituted aralkynyl,
optionally substituted carbocyclyl, optionally substituted
carbocyclylalkyl, optionally substituted heterocyclyl, optionally
substituted heterocyclylalkyl, optionally substituted heteroaryl,
optionally substituted heteroarylalkyl, --R.sup.b--OR.sup.a,
--R.sup.b--SR.sup.a, --R.sup.b--OC(O)--R.sup.a,
--R.sup.b--N(R.sup.a).sub.2, --R.sup.b--C(O)R.sup.a,
--R.sup.b--C(O)OR.sup.a, --R.sup.b--C(O)N(.sub.Ra).sub.2,
--R.sup.b--O--R.sup.c--C(O)N(R.sup.a).sub.2, --R.sup.b--N(R.sup.a)
C(O)OR.sup.a, --R.sup.b--N(R.sup.a)C(O)R.sup.a),
--R.sup.b--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--R.sup.b--S(O).sub.tOR.sup.a (where t is 1 or 2) and
--R.sup.b--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), where
each R.sup.a is independently hydrogen, alkyl, fluoroalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl, each R.sup.b is
independently a direct bond or a straight or branched alkylene or
alkenylene chain, and R.sup.c is a straight or branched alkylene or
alkenylene chain, and where each of the above substituents is
unsubstituted unless otherwise indicated.
[0103] "Carbocyclylalkyl" refers to a radical of the formula
--R.sup.c-carbocyclyl where R.sup.c is an alkylene chain as defined
above. The alkylene chain and the carbocyclyl radical is optionally
substituted as defined above.
[0104] "Halo" or "halogen" refers to bromo, chloro, fluoro or iodo
substituents.
[0105] "Fluoroalkyl" refers to an alkyl radical, as defined above,
that is substituted by one or more fluoro radicals, as defined
above, for example, trifluoromethyl, difluoromethyl,
2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
The alkyl part of the fluoroalkyl radical may be optionally
substituted as defined above for an alkyl group.
[0106] "Heterocyclyl" refers to a stable 3- to 18-membered
non-aromatic ring radical that comprises two to twelve carbon atoms
and from one to six heteroatoms selected from nitrogen, oxygen and
sulfur. Unless stated otherwise specifically in the specification,
the heterocyclyl radical is a monocyclic, bicyclic, tricyclic or
tetracyclic ring system, which may include fused or bridged ring
systems. The heteroatoms in the heterocyclyl radical may be
optionally oxidized. One or more nitrogen atoms, if present, are
optionally quaternized. The heterocyclyl radical is partially or
fully saturated. The heterocyclyl may be attached to the rest of
the molecule through any atom of the ring(s). Examples of such
heterocyclyl radicals include, but are not limited to, dioxolanyl,
thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl,
imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl,
octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl,
2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl,
piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl,
quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl,
tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl,
1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated
otherwise specifically in the specification, the term
"heterocyclyl" is meant to include heterocyclyl radicals as defined
above that are optionally substituted by one or more sub stituents
selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo,
thioxo, cyano, nitro, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted aralkenyl, optionally
substituted aralkynyl, optionally substituted carbocyclyl,
optionally substituted carbocyclylalkyl, optionally substituted
heterocyclyl, optionally substituted heterocyclylalkyl, optionally
substituted heteroaryl, optionally substituted heteroarylalkyl,
--R.sup.b--OR.sup.a, --R.sup.b--SR.sup.a,
--R.sup.b--OC(O)--R.sup.a, --R.sup.b--N(R.sup.a).sub.2,
--R.sup.b--C(O)R.sup.a, --R.sup.bC(O)OR.sup.a,
--R.sup.b--C(O)N(R.sup.a).sub.2,
--R.sup.b--O--R.sup.c--C(O)N(R.sup.a).sub.2,
--R.sup.b--N(R.sup.a)C(O)OR.sup.a,
--R.sup.b--N(R.sup.a)C(O)R.sup.a,
--R.sup.b--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--R.sup.b--S(O).sub.tOR.sup.a (where t is 1 or 2) and
--R.sup.b--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), where
each R.sup.a is independently hydrogen, alkyl, fluoroalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl, each R.sup.b is
independently a direct bond or a straight or branched alkylene or
alkenylene chain, and R.sup.c is a straight or branched alkylene or
alkenylene chain, and where each of the above substituents is
unsubstituted unless otherwise indicated.
[0107] "N-heterocyclyl" or "N-attached heterocyclyl" refers to a
heterocyclyl radical as defined above containing at least one
nitrogen and where the point of attachment of the heterocyclyl
radical to the rest of the molecule is through a nitrogen atom in
the heterocyclyl radical. An N-heterocyclyl radical is optionally
substituted as described above for heterocyclyl radicals. Examples
of such N-heterocyclyl radicals include, but are not limited to,
1-morpholinyl, 1-piperidinyl, 1-piperazinyl, 1-pyrrolidinyl,
pyrazolidinyl, imidazolinyl, and imidazolidinyl.
[0108] "C-heterocyclyl" or "C-attached heterocyclyl" refers to a
heterocyclyl radical as defined above containing at least one
heteroatom and where the point of attachment of the heterocyclyl
radical to the rest of the molecule is through a carbon atom in the
heterocyclyl radical. A C-heterocyclyl radical is optionally
substituted as described above for heterocyclyl radicals. Examples
of such C-heterocyclyl radicals include, but are not limited to,
2-morpholinyl, 2- or 3- or 4-piperidinyl, 2-piperazinyl, 2- or
3-pyrrolidinyl, and the like.
[0109] "Heterocyclylalkyl" refers to a radical of the formula
R.sup.c-heterocyclyl where R.sup.c is an alkylene chain as defined
above. If the heterocyclyl is a nitrogen-containing heterocyclyl,
the heterocyclyl is optionally attached to the alkyl radical at the
nitrogen atom. The alkylene chain of the heterocyclylalkyl radical
is optionally substituted as defined above for an alkylene chain.
The heterocyclyl part of the heterocyclylalkyl radical is
optionally substituted as defined above for a heterocyclyl
group.
[0110] "Heteroaryl" refers to a radical derived from a 3- to
18-membered aromatic ring radical that comprises two to seventeen
carbon atoms and from one to six heteroatoms selected from
nitrogen, oxygen and sulfur. As used herein, the heteroaryl radical
may be a monocyclic, bicyclic, tricyclic or tetracyclic ring
system, wherein at least one of the rings in the ring system is
fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2)
7celectron system in accordance with the Hiickel theory. Heteroaryl
includes fused or bridged ring systems. The heteroatom(s) in the
heteroaryl radical is optionally oxidized. One or more nitrogen
atoms, if present, are optionally quaternized. The heteroaryl is
attached to the rest of the molecule through any atom of the
ring(s). Examples of heteroaryls include, but are not limited to,
azepinyl, acridinyl, benzimidazolyl, benzindolyl,
1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl,
benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl,
1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl,
benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl,
benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl),
benzothieno[3,2-d]pyrimidinyl, benzotriazolyl,
benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl,
cyclopenta[d]pyrimidinyl,
6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl,
5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl,
6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl,
dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl,
furo[3,2-c]pyridinyl,
5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl,
5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl,
5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl,isothiazolyl,
imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl,
isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl,
5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl,
1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl,
oxiranyl, 5,6,6a,7,8,9,10, 10a-octahydrobenzo [h] quinazolinyl,
1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl,
phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl,
pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl,
pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl,
tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl,
5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl,
6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl,
5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl,
thiadiazolyl, triazolyl, tetrazolyl, triazinyl,
thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl,
thieno[2,3-c]pridinyl, and thiophenyl (i.e. thienyl). Unless stated
otherwise specifically in the specification, the term "heteroaryl"
is meant to include heteroaryl radicals as defined above which are
optionally substituted by one or more sub stituents selected from
alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl,
haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted
aryl, optionally substituted aralkyl, optionally substituted
aralkenyl, optionally substituted aralkynyl, optionally substituted
carbocyclyl, optionally substituted carbocyclylalkyl, optionally
substituted heterocyclyl, optionally substituted heterocyclylalkyl,
optionally substituted heteroaryl, optionally substituted
heteroarylalkyl, --R.sup.b--OR.sup.a, --R.sup.b--SR.sup.a,
--R.sup.b--OC(O)--R.sup.a, --R.sup.b-13 N(R.sup.a).sub.2,
--R.sup.b--C(O)R.sup.a, --R.sup.b--C(O)OR.sup.a,
--R.sup.b--C(O)N(R.sup.a).sub.2,
--R.sup.b--O--R.sup.c--C(O)N(R.sup.a).sub.2,
--R.sup.b--N(R.sup.a)C(O)OR.sup.a, --R.sup.b-13
N(R.sup.a)C(O)R.sup.a, --R.sup.b-13 N(R.sup.a)S(O).sub.tR.sup.a
(where t is 1 or 2), --R.sup.b--S(O).sub.tOR.sup.a (where t is 1 or
2) and --R.sup.b--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2),
where each R.sup.a is independently hydrogen, alkyl, fluoroalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl, each R.sup.b is
independently a direct bond or a straight or branched alkylene or
alkenylene chain, and R.sup.c is a straight or branched alkylene or
alkenylene chain, and where each of the above substituents is
unsubstituted unless otherwise indicated.
[0111] "N-heteroaryl" refers to a heteroaryl radical as defined
above containing at least one nitrogen and where the point of
attachment of the heteroaryl radical to the rest of the molecule is
through a nitrogen atom in the heteroaryl radical. An N-heteroaryl
radical is optionally substituted as described above for heteroaryl
radicals.
[0112] "C-heteroaryl" refers to a heteroaryl radical as defined
above and where the point of attachment of the heteroaryl radical
to the rest of the molecule is through a carbon atom in the
heteroaryl radical. A C-heteroaryl radical is optionally
substituted as described above for heteroaryl radicals.
[0113] "Heteroarylalkyl" refers to a radical of the formula
--R.sup.c-heteroaryl, where R.sup.c is an alkylene chain as defined
above. If the heteroaryl is a nitrogen-containing heteroaryl, the
heteroaryl is optionally attached to the alkyl radical at the
nitrogen atom. The alkylene chain of the heteroarylalkyl radical is
optionally substituted as defined above for an alkylene chain. The
heteroaryl part of the heteroarylalkyl radical is optionally
substituted as defined above for a heteroaryl group.
[0114] The compounds, or their pharmaceutically acceptable salts
may contain one or more asymmetric centers and may thus give rise
to enantiomers, diastereomers, and other stereoisomeric forms that
may be defined, in terms of absolute stereochemistry, as (R)- or
(S)- or, as (D)- or (L)- for amino acids. When the compounds
described herein contain olefinic double bonds or other centers of
geometric asymmetry, and unless specified otherwise, it is intended
that the compounds include both E and Z geometric isomers (e.g.,
cis or trans.) Likewise, all possible isomers, as well as their
racemic and optically pure forms, and all tautomeric forms are also
intended to be included.
[0115] A "stereoisomer" refers to a compound made up of the same
atoms bonded by the same bonds but having different
three-dimensional structures, which are not interchangeable. It is
therefore contemplated that various stereoisomers and mixtures
thereof and includes "enantiomers," which refers to two
stereoisomers whose molecules are nonsuperimposeable mirror images
of one another.
[0116] A "tautomer" refers to a proton shift from one atom of a
molecule to another atom of the same molecule. The compounds
presented herein may exist as tautomers. Tautomers are compounds
that are interconvertible by migration of a hydrogen atom,
accompanied by a switch of a single bond and adjacent double bond.
In solutions where tautomerization is possible, a chemical
equilibrium of the tautomers will exist. The exact ratio of the
tautomers depends on several factors, including temperature,
solvent, and pH. Some examples of tautomeric pairs include:
##STR00007##
[0117] "Optional" or "optionally" means that a subsequently
described event or circumstance may or may not occur and that the
description includes instances when the event or circumstance
occurs and instances in which it does not. For example, "optionally
substituted aryl" means that the aryl radical may or may not be
substituted and that the description includes both substituted aryl
radicals and aryl radicals having no substitution.
[0118] "Pharmaceutically acceptable salt" includes both acid and
base addition salts. A pharmaceutically acceptable salt of any one
of the alkoxyphenyl-linked amine derivative compounds described
herein is intended to encompass any and all pharmaceutically
suitable salt forms. Preferred pharmaceutically acceptable salts of
the compounds described herein are pharmaceutically acceptable acid
addition salts and pharmaceutically acceptable base addition
salts.
[0119] "Pharmaceutically acceptable acid addition salt" refers to
those salts which retain the biological effectiveness and
properties of the free bases, which are not biologically or
otherwise undesirable, and which are formed with inorganic acids
such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid, hydroiodic acid, hydrofluoric acid,
phosphorous acid, and the like. Also included are salts that are
formed with organic acids such as aliphatic mono- and dicarboxylic
acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids,
alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic
acids, etc. and include, for example, acetic acid, trifluoroacetic
acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid,
maleic acid, malonic acid, succinic acid, fumaric acid, tartaric
acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,
salicylic acid, and the like. Exemplary salts thus include
sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates,
phosphates, monohydrogenphosphates, dihydrogenphosphates,
metaphosphates, pyrophosphates, chlorides, bromides, iodides,
acetates, trifluoroacetates, propionates, caprylates, isobutyrates,
oxalates, malonates, succinate suberates, sebacates, fumarates,
maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates,
dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates,
phenylacetates, citrates, lactates, malates, tartrates,
methanesulfonates, and the like. Also contemplated are salts of
amino acids, such as arginates, gluconates, and galacturonates
(see, for example, Berge S.M. et al., "Pharmaceutical Salts,"
Journal of Pharmaceutical Science, 66:1-19 (1997), which is hereby
incorporated by reference in its entirety). Acid addition salts of
basic compounds may be prepared by contacting the free base forms
with a sufficient amount of the desired acid to produce the salt
according to methods and techniques with which a skilled artisan is
familiar.
[0120] "Pharmaceutically acceptable base addition salt" refers to
those salts that retain the biological effectiveness and properties
of the free acids, which are not biologically or otherwise
undesirable. These salts are prepared from addition of an inorganic
base or an organic base to the free acid. Pharmaceutically
acceptable base addition salts may be formed with metals or amines,
such as alkali and alkaline earth metals or organic amines. Salts
derived from inorganic bases include, but are not limited to,
sodium, potassium, lithium, ammonium, calcium, magnesium, iron,
zinc, copper, manganese, aluminum salts and the like. Salts derived
from organic bases include, but are not limited to, salts of
primary, secondary, and tertiary amines, substituted amines
including naturally occurring substituted amines, cyclic amines and
basic ion exchange resins, for example, isopropylamine,
trimethylamine, diethylamine, triethylamine, tripropylamine,
ethanolamine, diethanolamine, 2-dimethylaminoethanol,
2-diethylaminoethanol, dicyclohexylamine, lysine, arginine,
histidine, caffeine, procaine, N,N-dibenzylethylenediamine,
chloroprocaine, hydrabamine, choline, betaine, ethylenediamine,
ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine,
theobromine, purines, piperazine, piperidine, N-ethylpiperidine,
polyamine resins and the like. See Berge et al., supra.
[0121] "Non-retinoid compound" refers to any compound that is not a
retinoid. A retinoid is a compound that has a diterpene skeleton
possessing a trimethylcyclohexenyl ring and a polyene chain that
terminates in a polar end group. Examples of retinoids include
retinaldehyde and derived imine/hydrazide/oxime, retinol and any
derived ester, retinyl amine and any derived amide, retinoic acid
and any derived ester or amide. A non-retinoid compound can
comprise though not require an internal cyclic group (e.g.,
aromatic group). A non-retinoid compound can contain though not
require an alkoxyphenyl-linked amine group.
[0122] As used herein, "treatment" or "treating," or "palliating"
or "ameliorating" are used interchangeably herein. These terms
refers to an approach for obtaining beneficial or desired results
including but not limited to therapeutic benefit and/or a
prophylactic benefit. By "therapeutic benefit" is meant eradication
or amelioration of the underlying disorder being treated. Also, a
therapeutic benefit is achieved with the eradication or
amelioration of one or more of the physiological symptoms
associated with the underlying disorder such that an improvement is
observed in the patient, notwithstanding that the patient may still
be afflicted with the underlying disorder. For prophylactic
benefit, the compositions may be administered to a patient at risk
of developing a particular disease, or to a patient reporting one
or more of the physiological symptoms of a disease, even though a
diagnosis of this disease may not have been made.
[0123] "Prodrug" is meant to indicate a compound that may be
converted under physiological conditions or by solvolysis to a
biologically active compound described herein. Thus, the term
"prodrug" refers to a precursor of a biologically active compound
that is pharmaceutically acceptable. A prodrug may be inactive when
administered to a subject, but is converted in vivo to an active
compound, for example, by hydrolysis. The prodrug compound often
offers advantages of solubility, tissue compatibility or delayed
release in a mammalian organism (see, e.g., Bundgard, H., Design of
Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
[0124] A discussion of prodrugs is provided in Higuchi, T., et al.,
"Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series,
Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward
B. Roche, American Pharmaceutical Association and Pergamon Press,
1987, both of which are incorporated in full by reference
herein.
[0125] The term "prodrug" is also meant to include any covalently
bonded carriers, which release the active compound in vivo when
such prodrug is administered to a mammalian subject. Prodrugs of an
active compound, as described herein, may be prepared by modifying
functional groups present in the active compound in such a way that
the modifications are cleaved, either in routine manipulation or in
vivo, to the parent active compound. Prodrugs include compounds
wherein a hydroxy, amino or mercapto group is bonded to any group
that, when the prodrug of the active compound is administered to a
mammalian subject, cleaves to form a free hydroxy, free amino or
free mercapto group, respectively. Examples of prodrugs include,
but are not limited to, acetate, formate and benzoate derivatives
of alcohol or amine functional groups in the active compounds and
the like.
Compounds of the Invention
[0126] One embodiment provides the compound, or tautomer,
stereoisomer, geometric isomer, pharmaceutically acceptable
solvate, hydrate, salt, polymorph, N-oxide or prodrug thereof,
selected from:
##STR00008## ##STR00009##
Compositions of the Method
[0127] One embodiment provides a method of treating an ophthalmic
disease or disorder comprising administration of a compound of
Formula (I) or a tautomer, stereoisomer, geometric isomer or
pharmaceutically acceptable solvate, hydrate, salt, polymorph,
N-oxide or prodrug thereof:
##STR00010## [0128] wherein, [0129] Z is a bond,
--C(R.sup.1)(R.sup.2)--,
--C(R.sup.9)(R.sup.10)--C(R.sup.1)(R.sup.2)--,
--X--C(R.sup.31)(R.sup.32)--,
--C(R.sup.9)(R.sup.10)--C(R.sup.1)(R.sup.2)--C(R.sup.36)(R.sup.37)--
or --X--C(R.sup.31)(R.sup.32)--C(R.sup.1)(R.sup.2)--; [0130]
R.sup.1 and R.sup.2 are each independently selected from hydrogen,
halogen, C.sub.1-C.sub.5 alkyl, fluoroalkyl, --OR.sup.6 or
--NR.sup.7R.sup.8, or R.sup.1 and R.sup.2 together form an oxo;
[0131] R.sup.31 and R.sup.32 are each independently selected from
hydrogen, C.sub.1-C.sub.5 alkyl, or fluoroalkyl; [0132] R.sup.36
and R.sup.37 are each independently selected from hydrogen,
halogen, C.sub.1-C.sub.5 alkyl, fluoroalkyl, --OR.sup.6 or
--NR.sup.7R.sup.8, or R.sup.36 and R.sup.37 together form an oxo;
or optionally, R.sup.36 and R.sup.1 together form a direct bond to
provide a double bond; or optionally, R.sup.36 and R.sup.1 together
form a direct bond, and R.sup.37 and R.sup.2 together form a direct
bond to provide a triple bond; [0133] R.sup.3 and R.sup.4 are each
independently selected from hydrogen, alkyl, alkenyl, fluoroalkyl,
aryl, heteroaryl, carbocyclyl or C-attached heterocyclyl; or
R.sup.3 and R.sup.4 together with the carbon atom to which they are
attached, form a carbocyclyl or heterocyclyl; or R.sup.3 and
R.sup.4 together form an imino; [0134] R.sup.5 is C.sub.1-C.sub.15
alkyl, carbocyclyalkyl, arylalkyl, heteroaryl alkyl or
heterocyclylalkyl; [0135] R.sup.7 and R.sup.8 are each
independently selected from hydrogen, alkyl, carbocyclyl,
heterocyclyl, --C(.dbd.O)R.sup.13, SO.sub.2R.sup.13,
CO.sub.2R.sup.13 or SO.sub.2NR.sup.24R.sup.25; or R.sup.7 and
R.sup.8 together with the nitrogen atom to which they are attached,
form an N-heterocyclyl; [0136] X is --O--, --S--, --S(.dbd.O)--,
--S(.dbd.O).sub.2--, --N(R.sup.30)--, --C(.dbd.CH.sub.2)--,
--C(.dbd.N--NR.sup.35)--, or --C(.dbd.N--OR.sup.35)--; [0137]
R.sup.9 and R.sup.l.degree. are each independently selected from
hydrogen, halogen, alkyl, fluoroalkyl, --OR.sup.19,
--NR.sup.2R.sup.21 or carbocyclyl; or R.sup.9 and R.sup.10 form an
oxo; or optionally, R.sup.9 and R.sup.1 together form a direct bond
to provide a double bond; or optionally, R.sup.9 and R.sup.1
together form a direct bond, and R.sup.10 and R.sup.2 together form
a direct bond to provide a triple bond; [0138] R.sup.11 nd R.sup.12
are each independently selected from hydrogen, alkyl, carbocyclyl,
--C(.dbd.O)R.sup.23, --C(NH)NH.sub.2, SO.sub.2R.sup.23,
CO.sub.2R.sup.23 or SO.sub.2NR.sup.28R.sup.29; or R.sup.11 and
R.sup.12, together with the nitrogen atom to which they are
attached, form an N-heterocyclyl; [0139] each R.sup.13, R.sup.22
and R.sup.23 is independently selected from alkyl, heteroalkyl,
alkenyl, aryl, aralkyl, carbocyclyl, heteroaryl or heterocyclyl;
[0140] R.sup.6, R.sup.19, R.sup.39, R.sup.34 and R.sup.35 are each
independently hydrogen or alkyl; [0141] R.sup.20 and R.sup.21 are
each independently selected from hydrogen, alkyl, carbocyclyl,
heterocyclyl, --C(.dbd.O)R.sup.22, SO.sub.2R.sup.22,
CO.sub.2R.sup.22 or SO.sub.2NR.sup.26R.sup.27; or R.sup.20 and
R.sup.21 together with the nitrogen atom to which they are
attached, form an N-heterocyclyl; and [0142] each R.sup.24,
R.sup.25, R.sup.26, R.sup.27, R.sup.28 and R.sup.29 is
independently selected from hydrogen, alkyl, alkenyl, fluoroalkyl,
aryl, heteroaryl, carbocyclyl or heterocyclyl; [0143] each R.sup.33
is independently selected from halogen, OR.sup.34, alkyl, or
fluoroalkyl; and n is 0, 1, 2, 3, or 4.
[0144] Another embodiment provides for the method wherein the
compound of Formula (I) has the structure of Formula (II):
##STR00011## [0145] wherein, [0146] R.sup.1 and R.sup.2 are each
independently selected from hydrogen, halogen, C.sub.1-C.sub.5
alkyl, fluoroalkyl, --OR.sup.6 or --NR.sup.7R.sup.8; or R.sup.1 and
R.sup.2 together form an oxo; [0147] R.sup.3 and R.sup.4 are each
independently selected from hydrogen or alkyl; or R.sup.3 and
R.sup.4 together form an imino; [0148] R.sup.7 and R.sup.8 are each
independently selected from hydrogen, alkyl, carbocyclyl or
--C(.dbd.O)R.sup.13; or R.sup.7 and R.sup.8, together with the
nitrogen atom to which they are attached, form an N-heterocyclyl;
[0149] R.sup.9 and R.sup.10 are each independently selected from
hydrogen, halogen, alkyl, fluoroalkyl, --OR.sup.19,
--NR.sup.20R.sup.21 or carbocyclyl; or R.sup.9 and R.sup.10
together form an oxo; [0150] R.sup.11 and R.sup.12 are each
independently selected from hydrogen, alkyl, carbocyclyl or
--C(.dbd.O)R.sup.23; or R.sup.11 and R.sup.12, together with the
nitrogen atom to which they are attached, form an N-heterocyclyl;
[0151] each R.sup.13, R.sup.22 and R.sup.23 is independently
selected from alkyl, alkenyl, aryl, aralkyl, carbocyclyl,
heteroaryl or heterocyclyl; [0152] R.sup.6, R.sup.19 and R.sup.34
are each independently hydrogen or alkyl; [0153] R.sup.20 and
R.sup.21 are each independently selected from hydrogen, alkyl,
carbocyclyl, --C(.dbd.O)R.sup.22; or R.sup.20 and R.sup.21,
together with the nitrogen atom to which they are attached, form an
N-heterocyclyl; and [0154] each R.sup.24, R.sup.25, R.sup.26,
R.sup.27, R.sup.28 and R.sup.29 is independently selected from
hydrogen, alkyl, alkenyl, fluoroalkyl, aryl, heteroaryl,
carbocyclyl or heterocyclyl; [0155] R.sup.14 and R.sup.15 are each
independently selected from hydrogen or alkyl; [0156] R.sup.16 and
R.sup.17 are each independently selected from hydrogen,
C.sub.1-C.sub.13 alkyl, halo or fluoroalkyl; or R.sup.16 and
R.sup.17, together with the carbon to which they are attached form
a carbocyclyl; [0157] each R.sup.33 is independently selected from
halogen, OR.sup.34, alkyl, or fluoroalkyl; and n is 0, 1, 2, 3, or
4; and [0158] R.sup.18 is selected from a hydrogen, alkyl, alkoxy,
hydroxy, halo or fluoroalkyl.
[0159] Another embodiment provides for the method wherein the
compound of Formula (II) is further defined as R.sup.1 and R.sup.2
are each independently selected from hydrogen, halogen,
C.sub.1-C.sub.5 alkyl, or --OR.sup.6; R.sup.9 and R.sup.10 are each
independently selected from hydrogen, halogen, alkyl, or
--OR.sup.19; or R.sup.9 and R.sup.10 together form an oxo; R.sup.6
and R.sup.19 are each independently hydrogen or alkyl; R.sup.16 and
R'.sup.7, together with the carbon to which they are attached form
a carbocyclyl; and R.sup.18 is selected from a hydrogen, alkoxy or
hydroxy.
[0160] Another embodiment provides for the method wherein the
compound of Formula (II) is further defined as R.sup.16 and
R.sup.17, together with the carbon to which they are attached, form
a cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl,
and R.sup.18 is hydrogen or hydroxy.
[0161] Another embodiment provides for a method wherein the
compound of Formula (II) is
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol.
##STR00012##
[0162] (R)-3-amino-1-(3-(cyclohexylm ethoxy)phenyl)propan-1-ol
[0163] In another aspect is the method for treating an ophthalmic
disease or disorder comprising administration of a non-retinoid
compound wherein the non-retinoid compound, or tautomer,
stereoisomer, geometric isomer, pharmaceutically acceptable
solvate, hydrate, salt, polymorph, N-oxide or prodrug thereof, is
selected from the group consisting of:
##STR00013## ##STR00014##
Methods of Treatment
[0164] In one aspect is a method of treating an ophthalmic disease
or disorder comprising administration of a non-retinoid compound
resulting in a normalized electroretinogram response from about 5%
to about 55% after about 12 hours to about 48 hours post
administration of said non-retinoid compound. In another aspect is
the method wherein the normalized electroretinogram response is
from about 5% to about 15%. In another aspect is the method wherein
the normalized electroretinogram response is from about 15% to
about 25%. In another aspect is the method wherein the normalized
electroretinogram response is from about 25% to about 35%. In
another aspect is the method wherein the normalized
electroretinogram response is from about 35% to about 55%. In
another aspect is the method wherein the normalized
electroretinogram response is determined after about 12 hours to
about 16 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 2 hours to
about 12 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 16 hours to
about 20 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 20 hours to
about 24 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 24 hours to
about 30 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 30 hours to
about 36 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 36 hours to
about 42 hours post administration of said non-retinoid compound.
In another aspect is the method wherein the normalized
electroretinogram response is determined after about 42 hours to
about 48 hours post administration of said non-retinoid
compound.
[0165] In one aspect is a method of treating an ophthalmic disease
or disorder comprising administration of a single dose of a
non-retinoid compound resulting in a normalized electroretinogram
response that is greater on day 1 than on day 2. In another aspect
is a method of treating an ophthalmic disease or disorder
comprising administration of a non-retinoid compound resulting in a
greater therapeutic response on day 2 than on day 1 after the
administration of a single dose. In another aspect is the method
wherein the therapeutic response is determined by
electroretinography.
[0166] In one aspect is a method of treating an ophthalmic disease
or disorder comprising administration of a non-retinoid compound
resulting in a normalized electroretinogram response less than
about 50% for a time period of about 4 hours to about 36 hours
after the plasma concentration of said non-retinoid compound has
declined to 0.3 C.sub.max.
[0167] FIG. 1 illustrates the linear scale plot of plasma
concentration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol vs time
after administration of a single oral dose, thus indicating that
this compound of Formula (I) is orally bioavailable over a wide
range of dosage amount and has a Cmax of about 4 hours and a
t.sub.1/2 of about 6-7 hours.
[0168] FIG. 2 illustrates the log scale plot of plasma
concentration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol vs time
after administration of a single oral dose.
[0169] FIG. 3 illustrates the single patient EGR response vs
retinal illumination time at days 1, 2 and 7, compared to baseline
(no drug treatment) after administration of a single oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. FIG. 3(a)
is for the 20 mg dose; FIG. 3(b) is for the 40 mg dose; and FIG.
3(c) is for the 60 mg dose. The EGR determinations for days 1 and 2
were performed at 4 hours and 24 hours post dose, respectively. The
EGR determinations clearly indicated a pronounced pharmacodynamic
effect at day 2 (24 post dose) that has subsided by day 7.
Comparison to blood levels provided in FIGS. 1 and 2 indicate a
pharmacodynamic effect with little to no compound in the blood.
[0170] FIG. 4 illustrates the normalized EGR response vs retinal
illumination time at day 1 (4 hours post dosing), compared to
baseline (no drug treatment) after administration of a single oral
dose of (R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. The
doses examined are 20 mg, 40 mg, 60 mg and 75 mg. FIG. 5
illustrates the normalized EGR response vs retinal illumination
time at day 2 (24 hours post dosing), compared to baseline (no drug
treatment) after administration of a single oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. The doses
examined are 20 mg, 40 mg, 60 mg and 75 mg. Comparison of FIGS. 4
and 5 indicate that the pharmacological effect is more pronounced
on day 2 than on day 1. Comparison to blood levels provided in
FIGS. 1 and 2 indicate a pharmacodynamic effect with little to no
compound in the blood.
[0171] FIG. 6 is a table comparing the inhibition of normalized EGR
response after 30 minutes of retinal illumination vs single oral
dose of (R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. Day
1 measurements were obtained at 4 hours post dose and day 2
measurements were obtained at 24 hours post dose. Note for
comparison to FIGS. 4 and 5 that % inhibition=(100-normalized EGR
response).
[0172] FIG. 7 illustrates the normalized EGR response vs retinal
illumination time, compared to baseline (no drug treatment) after
administration of a single 75 mg oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol at 1 day (4
hours post dose), day 2 (24 hours post dose), day 4 and day 7. The
data presented in FIG. 7 indicate a pharmacodynamic effect that is
greater on day 2 than on day 1 but by day 4 has subsided.
[0173] FIG. 8 is a table comparing the inhibition of normalized EGR
response after 30 minutes of retinal illumination vs length of time
after administration of a single 75 mg oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol. Day 1
measurements were obtained at 4 hours post dose and day 2
measurements were obtained at 24 hours post dose. FIG. 8 is a
tabular summary of the data presented in FIG. 7. Note for
comparison to FIG. 6 that % inhibition=(100-normalized EGR
response).
Dosing Schedule
[0174] Provided in one embodiment is a method for determining the
dose of non-retinoid visual cycle modulator to be administered for
the treatment of an ophthalmic disease or disorder comprising
determining the normalized electroretinogram response from about 12
hours to about 48 hours after the administration of a single dose
of said non-retinoid visual cycle modulator.
[0175] In another aspect are dosing schedules (e.g., number of
administrations per day) for the treatment of the ophthalmic
diseases and conditions described herein. In one embodiment, the
compound is administered once daily (which includes multiple
sub-doses of the compound administered at approximately the same
time); in another embodiment, the compound is administered once
every two days (which includes multiple sub-doses of the compound
administered at approximately the same time); and in another
embodiment, the compound is administered once every three days or
more (which includes multiple sub-doses of the compound
administered at approximately the same time).
[0176] In another aspect are dosing schedules (e.g., variations
between dose amounts of subsequent administrations) for the
treatment of the ophthalmic diseases and conditions described
herein. In one embodiment, the compound is administered on day 1 at
a dose level twice that adminstered on following days (e.g., a
loading dose). In another embodiment, the compound is administered
on day 1 at a dose level three times that adminstered on following
days.
[0177] In another aspect are dosing schedules (e.g., time of day
when compound is administered) for the treatment of the ophthalmic
diseases and conditions described herein. In one embodiment, the
compound is administered in the morning; in another embodiment, the
compound is administered in the evening; in another embodiment, the
compound is administered upon waking; and in another embodiment,
the compound is administered prior to going to sleep. In one
embodiment, the compound is administered as a controlled release
formulation in the evening. In one embodiment, the compound is
administered as a controlled release formulation in the evening
prior to going to bed. In another embodiment, the compound is
administered prior to eating, or alternatively during a meal, or
alternatively, subsequent to a meal. In some embodiments, such a
meal is breakfast; in other embodiments, such a meal is lunch; in
yet other embodiments, such a meal is dinner/supper.
[0178] In one aspect the daily dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol is about 4
mg to about 100 mg. In another aspect the daily dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol is about 5
mg; about 7 mg; about 15 mg; about 20 mg; about 40 mg; about 60 mg;
about 75 mg; and about 100 mg. In another aspect the daily dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol is about 100
mg; about 150 mg; about 200 mg; about 250 mg; about 300 mg; about
350 mg; and about 400 mg.
Drug Holiday
[0179] In certain circumstances, a physician skilled in the art of
treating ophthalmic diseases and disorders may, optionally, and
temporarily, suspend administration, or alternatively, reduce the
dose, of the compound of Formula (I) to effect a drug holiday. One
embodiment provides a dosing schedule for the treatment of an
ophthalmic disease or disorder comprising a drug holiday after from
about 3 months of continuous daily dosing to about 12 months of
continuous daily dosing. Another embodiment provides a dosing
schedule for the treatment of an ophthalmic disease or disorder
comprising a drug holiday wherein the drug holiday is a time period
of from about 3 days to about 21 days. Once improvement of the
patient's conditions has occurred, a maintenance dose is
administered if necessary. Subsequently, the dosage or the
frequency of administration, or both, can be reduced, as a function
of the symptoms, to a level at which the improved disease, disorder
or condition is retained.
Controlled Release Formulations
[0180] Provided in one embodiment is a controlled release solid
dosage formulation for the treatment of an ophthalmic disease or
disorder comprising a compound of Formula (I) wherein the plasma
T.sub.max is observed 12 hours post-dose. In another embodiment the
plasma T.sub.max is observed 10 hours post-dose. In another
embodiment the plasma T.sub.max is observed 14 hours post-dose.
[0181] Controlled release formulations which provide a delayed
release and thus a delayed plasma T.sub.max are known to those
skilled in the art of pharmaceutical compounding and formulation.
The controlled release pharmaceutical preparation described herein
comprises a core containing a compound of Formula (I) and a coating
layer containing a water-repellent salt and a water-insoluble and
slightly water-permeable acrylic polymer having
trimethylammoniumethyl group, which surrounds said core. If
desired, another coating layer of at least one material selected
from the group consisting of ethylcellulose, or
hydroxypropylcellulose may be provided around said coating
layer.
[0182] In the present application, a polymer of acrylic acid,
methyl acrylate, ethyl acrylate, methacrylic acid, methyl
methacrylate, ethyl methacrylate or the like, which has
trimethylammoniumethyl group in the molecule, may be used as a
water-insoluble and slightly water-permeable acrylic polymer
constituting the coating layer. For instance, a copolymer of ethyl
acrylate, methyl methacrylate and
.beta.-acryloyloxyethyltrimethylammonium chloride in which about
0.025 to about 0.033 mole of
.beta.-acryloyloxyethyltrimethylammonium chloride is contained per
mole of the other neutral acrylic monomers is preferably used. Such
copolymer is commercially available under trade mark "Eudragit RS"
from Rohm Pharma, Germany or the like. The above-mentioned polymer
may contain, for instance, a small quantity of a water-permeable
polymer. Such copolymer is, for example, commercially available
under trade mark "Eudragit RL" from Rohm Pharma, Germany or the
like.
[0183] As ethylcellulose or hydroxypropylcellulose which is a
material of another coating layer provided around the coating layer
of an acrylic polymer, for instance, ethylcellulose containing
about 46.5 to about 51.0% of ethoxy group, hydroxypropylcellulose
containing about 53.4 to about 77.5% of hydroxypropoxy group or the
like can be suitably used.
[0184] As a water-repellent salt which constitute the coating layer
with an acrylic polymer, a salt of higher fatty acid and an
alkaline earth metal is preferably used. Examples of the salts are
calcium stearate, magnesium stearate and the like.
[0185] One embodiment provides, the above-mentioned acrylic polymer
and the water-repellent salt in the coating layer in a ratio about
0.5 to about 5 parts by weight. Another embodiment provides the
above-mentioned acrylic polymer and the water-repellent salt in the
coating layer in a ratio about 1.5 to about 4.5 parts by weight.
Another embodiment provides the above-mentioned acrylic polymer and
the water-repellent salt in the coating layer in a ratio about 2 to
about 4 parts by weight of the acrylic polymer is contained per
part by weight of the water-repellent salt.
[0186] The amount of the coating layer for the core depends on the
form or the size of the core. It is preferable that the amount of
the coating layer to be used increase depending on the increase of
the surface area per unit weight, that is, the decrease of the
particle size of the core. For example, in case of spherical
particles having mean particle size of about 500 to about 1000
micrometer, the amount of the coating layer is about 5 to about
80%, preferably about 7 to about 50%, in particular, preferably
about 8 to about 30%, based on the weight of the core.
[0187] In the present application, the form of the core to be
coated is not particularly limited and various forms such as plain
tablet, pill, granule and fine granule may be suitably used.
Granulated cores having mean particle size of about 300 to about
5000 micrometer, in particular, about 500 to about 1500 micrometer
may be used.
[0188] In addition, various additives such as an excipient, a
binder, a lubricant, an aggregation-preventing agent and a
solubilizer may be contained in the core.
[0189] Examples of excipients are sugars such as sucrose, lactose,
mannitol and glucose, starch, crystalline cellulose, calcium
phosphate, calcium sulfate, calcium lactate and the like. Examples
of carriers for regulating particle sizes are sucrose, lactose,
starch, crystalline cellulose and the like. Examples of binders are
polyvinylalcohol, polyacrylic acid, polymethacrylic acid,
polyvinylpyrrolidone, glucose, sucrose, lactose, maltose, sorbitol,
mannitol, hydroxyethylcellulose, hydroxypropylmethylcellulose,
hydroxypropylcellulose, macrogols, arabic gum, gelatin, agar,
starch and the like. Examples of lubricants are stearic acid, talc
and the like. Examples of aggregation-preventing agents are the
above-mentioned lubricants, silicone dioxide, colloidal silicone
dioxide and the like. Examples of solubilizers are organic acids
such as fumaric acid, succinic acid and malic acid and the
like.
[0190] The pharmaceutical preparation of the present invention can
be prepared by coating cores containing a compound of Formula (I)
with a dispersion of a water-insoluble and slightly water-permeable
acrylic polymer having trimethylammoniumethyl group and a
water-repellent salt. The preparation of the cores can be carried
out according to the usual procedure for the preparation, for
example, as described in Remingtons Pharmaceutical Sciences 17,
1603-1632, 1633-1643 (Mack Publishing Company, published in 1985).
For example, the cores can be prepared by granulating the
composition of a medicinal compound, a binder and other additives
such as an excipient according to the method of wet oscillating
granulation, rotating granulation, fluidizing bed granulation or
the like to obtain granules. Alternatively, for example, the cores
may be prepared using carriers for regulating particle sizes
wherein spherically granulated carriers may be coated with a
compound of Formula (I) according to the usual method such as
powder coating method to obtain the cores. Powder coating can be
carried out, for instance, by gradually adding a compound of
Formula (I) and suitable additives such as an excipient with
spraying a solution obtained by dissolving a binder in a suitable
solvent such as water, a lower alcohol such as methanol, ethanol,
propanol, isopropanol or butanol, a lower alkanone such as acetone
or methylethylketone, chloroform, dichloromethane, dichloroethane
or a mixture thereof, on carrier particles to be cores, according
to the method of rotating granulation, pan coating, fluidizing bed
coating or the like.
[0191] The coating for thus obtained cores can be carried out by
adhering a dispersion of a water-repellent salt and an acrylic
polymer to the cores followed by drying.
[0192] As a dispersion medium for the above-mentioned component of
the coating layer, water, an alcohol such as methanol, ethanol or
propanol, a ketone such as acetone, a halogenated hydrocarbon such
as methylenechloride or chloroform, a mixture thereof or the like
is exemplified. Water, an alcohol or a mixture thereof is
preferable, and ethanol or a mixture of ethanol and water is
particularly preferable.
[0193] The coating can be carried out according to a method
generally used in the art for preparation such as the method of
fluidizing bed coating or pan coating. For example, in case of the
method of fluidizing bed coating, the coating can be carried out as
follows: the cores are fluidized in an apparatus by means of air
pressure, they are spray-coated with an aqueous dispersion of a
water-repellent salt and an acrylic acid polymer at an adequate
rate from the nozzle of the spray-gun.
[0194] The concentration of a water-repellent salt and an acrylic
polymer in the dispersion is not particularly limited, but it is
preferable that these components are added within the
above-mentioned scope of the preferable proportion of both
components, to be the concentration of about 5 to about 40% by
weight. In addition, a plasticizer, a coloring agent and the like
may be contained in the dispersion. As a plasticizer, for instance,
triacetin, triethyl citrate, acetyltributyl citrate, diethyl
phthalate, polyethyleneglycol, polysorbate or the like can be
suitably used. The amount of the plasticizer to be used is
preferably about 5 to about 40% by weight based on the weight of an
acrylic polymer.
[0195] The drying of thus obtained coating layer can be easily
carried out, for example, by heating at about 35.degree. C. to
about 100.degree. C., particularly about 40.degree. C. to about
70.degree. C.
[0196] Thus obtained controlled release pharmaceutical preparation
of the present invention may be administered as it is or in a form
filled in capsules.
[0197] The controlled release pharmaceutical preparation described
herein has the following characteristics because of its coating
layer of a slightly water-permeable acrylic polymer. That is, a
compound of Formula (I) rapidly dissolves from the preparation only
after a certain period which depends upon the amount of the coating
layer. The time until the start of the dissolution of a compound of
Formula (I) is optionally adjustable by changing the amount of the
coating layer.
Ophthalmic Disease or Disorder
[0198] In one embodiment the ophthalmic disease or disorder is
selected from retinal detachment, hemorrhagic retinopathy,
retinitis pigmentosa, cone-rod dystrophy, Sorsby's fundus
dystrophy, optic neuropathy, inflammatory retinal disease, diabetic
retinopathy, diabetic maculopathy, retinal blood vessel occlusion,
retinopathy of prematurity, ischemia reperfusion related retinal
injury, proliferative vitreoretinopathy, retinal dystrophy,
hereditary optic neuropathy, Sorsby's fundus dystrophy, uveitis, a
retinal injury, a retinal disorder associated with Alzheimer's
disease, a retinal disorder associated with multiple sclerosis, a
retinal disorder associated with Parkinson's disease, a retinal
disorder associated with viral infection, a retinal disorder
related to light overexposure, myopia, and a retinal disorder
associated with AIDS. In another embodiment, the ophthalmic disease
or disorder is age-related macular degeneration or Stargardt's
macular dystrophy. In an additional embodiment, the ophthalmic
disease or disorder is dry age-related macular degeneration. In an
additional embodiment, the ophthalmic disease or disorder is
diabetic retinopathy.
EXAMPLES
Example 1
Phase 1A Study of Safety and Pharmacodynamics Effect
[0199] A single-center, randomized, double masked, placebo
controlled, dose-escalating Phase 1A study to determine the safety
and pharmacodynamic effect of single dose oral
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol as measured
by dark-adapted electroretinogram (ERG) was performed. Study
participants were healthy volunteers of both genders, aged 55-80,
weighing between 50 and 110 kg. Major exclusion criteria included
other ocular conditions (e.g. cataracts, glaucoma, uveitis,
diabetic retinopathy, active conjunctivitis), change in
prescription chronic medications within the preceeding 28 days,
treatment with a retinoid compound within the last year, treatment
with sildenafil citrate, tadalafil, or vardenafil citrate within
the last week, or concomitant treatment with hypnotics,
anti-depressants, psychoactive substances, digitalis glycosides,
L-DOPA, chloroquine, hydroxychloroquine, systemic corticosteroids,
topical anti-glaucoma medications, or medications for the treatment
of wet AMD. Eight cohorts were randomized 5:1/drug:placebo and
assigned to dosage cohorts of 2 mg, 7 mg, 10 mg, 2.times.20 mg, 40
mg, 60 mg, and 75 mg. Plasma concentration versus time was
determined and is shown in FIG. 9. Peak plasma concentrations (C.)
increased linearly with increasing dose. The test compound was
readily absorbed from the GI tract and median time to attain
C.sub.SX was about 4 hours. Mean terminal elimination half-life
(t.sub.1/2) was 4-6 hours across all doses.
[0200] ERG studies were performed prior to dosing, 4-6 hours
post-dose (Day 1 ERG), 24 hours post-dose (Day 2 ERG), optionally
on Day 4, and on Day 7 (144 hours post-dose) as outlined in FIG.
10. The Day 2 EGR response curve is provided in FIG. 11. For
patients given placebo, there was a rapid rise in amplitude such
that the response was 90% recovered by 20 minutes. For patients
given (R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol, there
was a clear dose-related slowing of the rate of recovery; i.e. the
slope of the recovery function became slower with increasing dose.
At the highest dose, the amplitude was still less than 10% of the
baseline response after 60 minutes. The pre-bleach amplitude is
indistinguishable from the pre-treatment value for the placebo, 10
mg and 20 mg groups; i.e. 40 minutes of dark adaptation was
sufficient to produce a comparable ERG to the pre-treatment
dark-adapted value. For the 40 mg dose, the pre-bleach amplitude
was less than 50% of the dark-adapted amplitude prior to treatment
i.e. 40 minutes of dark-adaptation after normal room light exposure
was not sufficient to produce the normal dark-adapted amplitude.
Higher doses had progressively more affect on the pre-bleach
amplitude; at 75 mg dose the amplitude was 11% baseline. A summary
of the ERG data from cohorts 3-8 over Days 1-7 is provided in FIG.
12.
[0201] A cone response curve determined on Day 2 is provided in
FIG. 13. Unlike rod amplitudes, cone amplitudes remain within 20%
of the pre-treatment amplitude for all doses. Doses of 40 mg and
higher may cause noticeable deficiencies in night vision. There is
no evidence that
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol will have a
detectable effect on sensitivity in photopic (daylight)
conditions.
Example 2
Treatment of Dry-Form Age Related Macular Degeneration
[0202] An individual diagnosed with dry-form age related macular
degeneration is treated with an oral dose of 5 mg
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol every
morning upon waking. On days 2, 4, 6, 8, 12, 18, 24 and 30 the
individual is subjected to an electroretinogram determination to
evaluate treatment response and the individual is monitored for
instances of delayed dark adaptation and achromatopsia, as well as
systemic adverse effects.
Example 3
Preparation of a Controlled Release Formulation
[0203] Nonpareil (granulated sucrose) having the diameter of 350 to
500 micrometers (80 g) is put into the centrifugal fluidizing type
granulating and coating apparatus and to this is gradually added a
fine powder of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol (900 g)
while spraying a solution of polyvinylpyrrolidone (20 g) dissolved
in a mixture of water and ethanol (3:2) (640 g). The nonpareil is
thus coated around its surface with
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol and is
obtained as a plain granule. This plain granule is spray-coated
with a solution containing 30 parts of Eudragit RS, 10 parts of
calcium stearate and 3 parts of triethyl citrate to obtain a
controlled release pharmaceutical formulation containing
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol.
[0204] While preferred embodiments of the present invention have
been shown and described herein, it will be obvious to those
skilled in the art that such embodiments are provided by way of
example only. Numerous variations, changes, and substitutions will
now occur to those skilled in the art without departing from the
invention. It should be understood that various alternatives to the
embodiments of the invention described herein may be employed in
practicing the invention. It is intended that the following claims
define the scope of the invention and that methods and structures
within the scope of these claims and their equivalents be covered
thereby.
Example 4
A Phase 1, Open-Label, Randomized, Two-Way Crossover, Food-Effect
and Pharmacokinetic Pilot Study Following a Single 25 mg Oral Dose
of (R)-3-Amino-1-(3-(Ccyclohexylmethoxy)Phenyl)Propan-1-ol in
Healthy Subjects
Objectives:
[0205] The objectives of this study were:
[0206] 1. to determine the effect of food on the pharmacokinetics
(PK) of a single oral dose of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol in normal
healthy subjects; and
[0207] 2. to further assess the safety of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol in normal
healthy subjects.
Study Design:
[0208] This was an open-label, randomized, 2-way crossover,
food-effect and PK study conducted in 12 healthy male and female
subjects under either fasted conditions (10-hour fast) or fed
conditions (after standard Food and Drug Administration [FDA]
high-fat breakfast).
Subjects Planned and Analyzed :
[0209] Twelve subjects were enrolled, completed the study, and were
included in the analyses of safety and PK.
Diagnosis and Main Criteria for Inclusion:
[0210] Subjects were male or female; between 25 and 55 years of age
(inclusive); with a body mass index (BMI) between 18.5 and 32.0
kg/m.sup.2; a non-smoker; and in good health based upon results of
medical history, physical examination, 12-lead electrocardiogram
(ECG; within normal limits), laboratory test results, and visual
status examinations.
Test Product Dose, Route, Lot Number:
[0211] Subjects received a single oral dose of 25 mg
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol with 240 mL
room temperature water after an approximately 10-hour fast and
after a standard FDA high-fat breakfast in a crossover design
according to a statistical randomization schedule.
Criteria for Evaluation:
[0212] Pharmacokinetic: For each subject, the following PK
parameters were calculated, whenever possible, using
noncompartmental methods: [0213] C.sub.max Maximum observed plasma
concentration. [0214] T.sub.max Time to maximum plasma
concentration. [0215] AUC.sub.0-t Area under the plasma
concentration-time curve from hour 0 to the last measurable plasma
concentration, calculated by the linear up/log down trapezoidal
rule. [0216] AUC.sub.0-28 Area under the plasma concentration-time
curve extrapolated to infinity, calculated using the formula:
[0216] A U C 0 - .infin. = A U C 0 - t + C t .lamda. z ##EQU00001##
[0217] where C.sub.t is the last measurable plasma concentration
and .lamda..sub.Z is the apparent terminal phase rate constant.
[0218] .lamda..sub.Z Apparent terminal phase rate constant, where
.lamda..sub.Z is the magnitude of the slope of the linear
regression of the log concentration versus time profile during the
terminal phase. [0219] t.sub.1/2 Apparent terminal elimination
half-life (whenever possible), where t.sub.1/2
=(ln2)/.lamda..sub.Z. [0220] CL/F Apparent oral clearance,
calculated as Dose/AUC.sub.0-.infin. in plasma.
[0221] Pharmacokinetic calculations were performed using the
commercial software WinNonlin (Pharsight Corporation, Version 5.2).
Pharmacokinetic analysis used actual times as recorded on the Case
Report Form. For PK analysis, concentration values below the level
of quantification (BLQs) at the beginning of the profile were set
to 0; any embedded BLQs (between 2 quantifiable concentrations) or
BLQs at the end of the profile were set to missing.
[0222] Safety: Safety procedures included adverse event (AE)
assessments, 12-lead ECGs, vital signs, physical examinations, and
laboratory assessments.
Statistical Methods:
[0223] General: Data listings are provided for PK and safety data.
Summary statistics were provided for data, if applicable. Subject
eligibility data collected only at Screening or Check-in were not
summarized in tables. Data analysis was performed using Statistical
Analysis Software (SAS.RTM.) Version 9.1.
[0224] Pharmacokinetic: Descriptive statistics (mean, standard
deviation [SD], and coefficient of variation [CV]) were calculated
for the PK parameters. All statistics are reported as unadjusted
values. Individual C.sub.ax, AUC.sub.0-t, and AUC.sub.0-.infin.
following administration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol under
fasting or fed state are presented graphically.
[0225] Safety: Descriptive statistics were calculated on the safety
data. No inferential statistical analyses were planned or
conducted.
Pharmacokinectic Results:
[0226] Administration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol with a high
fat meal in test Treatment B increased C.sub.max,
AUC.sub.0-.infin., and AUC.sub.0-t, on average, 9.0%, 12.0%, and
13.0%, respectively, compared to those in a fasted condition in the
reference Treatment A based on unadjusted means.
Safety Results:
[0227] Overall, 47 AEs were reported by 12 subjects, with 26 AEs
reported in Period 1 and 21 AEs reported in Period 2. Twenty-four
AEs were reported following administration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol in the
fasted state and 23 AEs were reported following administration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol in the fed
state. The AE with the highest reported incidence overall was
chromatopsia. All 12 subjects in this study reported at least 1 AE
in the eye disorders system organ class, including chromatopsia,
visual impairment, vision blurred, and tunnel vision.
[0228] All reported AEs were mild in severity. The relationship to
study drug of the reported AEs was: 1 unrelated AE, 4 possibly
related AEs, and 42 probably related AEs. There were no deaths or
SAES during this study and no AE led to study discontinuation. All
AEs resolved without treatment by the end of the study.
[0229] No clinically significant changes or findings were noted
from clinical laboratory evaluations, vital sign measurements,
physical examinations, or 12-lead ECGs for this study. Overall, the
changes in the clinical safety assessments were unremarkable.
Conclusions:
[0230] Administration of
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol with food in
test Treatment B increased C.sub.max, AUC.sub.0-.infin., and
AUC.sub.0-t, on average, 9.0%, 12.0%, and 13.0%, respectively,
compared to without food in the reference Treatment A based on
unadjusted means.
[0231] A single oral dose of 25 mg
(R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol was
generally well-tolerated when given to healthy subjects in both the
fed and fasted states.
* * * * *